[Hiring] Director, Patient Centred Outcomes @Jazz Pharmaceuticals

Role Description

The Director, Patient-Centered Outcomes is a high-visibility, scientific, and strategic leadership role within the Global Evidence & Value Generation (EVG) organization. Reporting to the Head of Patient-Centered Outcomes, this leader will architect and execute global clinical outcome assessment (COA), patient experience data (PED), and patient-reported outcome (PRO) strategies.

The primary mandate encompasses steering the patient-focused evidence strategies for Jazz's cornerstone oncology launch and lifecycle programs:

• Neuro-Oncology: Accelerating peri-launch evidence, label negotiation, and patient/caregiver-centric value demonstration in rare neuro-oncology (diffuse midline gliomas / DIPG).
• Oncology (Solid tumors): Driving registrational and lifecycle COA evidence generation across multiple solid tumor indications (including biliary tract cancer [BTC], gastroesophageal adenocarcinoma [GEA], breast cancer, and subsequent indication expansions).
• Oncology & Cross-Therapeutic Pipeline: Future-proofing early-phase assets (Phase 1b through Phase 2) by defining fit-for-purpose measurement strategies aligned to Target Product Profiles (TPPs).

This role requires a commercially astute and regulatory-experienced strategist capable of balancing scientific rigor with urgent commercial and market access timelines, demonstrating the humanistic value of Jazz therapies to Health Authorities, payers, clinicians, and patients globally.

Qualifications

• Minimum of 8–10+ years of dedicated experience in Patient-Centered Outcomes (PCO), Clinical Outcome Assessments (COAs), Patient-Reported Outcomes (PROs), or HEOR within a global biopharmaceutical company or premier specialized consultancy.
• Demonstrated success driving COA/PRO strategies for commercial launches, registrational oncology filings, or major lifecycle expansions in solid tumors (e.g., GI, breast, thoracic) and/or neuro-oncology.
• Direct experience authoring regulatory briefing documents, engaging with health authorities (FDA, EMA, PMDA), and navigating FDA PFDD guidances to support label claims and review procedures.
• Strong command of psychometric evaluation methods, mixed-methods research design, qualitative interviewing, and questionnaire development/validation.
• Deep understanding of how patient-reported evidence integrates into global payer requirements, HTA methodologies (e.g., EU JCA, NICE, CADTH, ICER), and commercial value narratives.
• Hands-on experience directing global eCOA/ePRO trial operations, vendor management, and protocol integration.
• Exceptional communication and presentation skills; proven ability to articulate complex psychometric data and strategic rationales to executive leadership, commercial stakeholders, and regulatory panels.

Requirements

• Advanced Degree (Required): Master’s degree (MS, MPH) or Doctoral degree (PhD, PharmD, MD) in Psychometrics, Health Outcomes Research, Health Economics, Epidemiology, Public Health, Behavioral Sciences, Psychology, or related quantitative/clinical discipline.
• Doctoral degree (PhD/PharmD) strongly preferred.

Benefits

• Medical, dental and vision insurance.
• 401k retirement savings plan.
• Flexible paid vacation.
• Discretionary annual cash bonus or incentive compensation (depending on the role).
• Discretionary equity grants in accordance with Jazz’s Long Term Equity Incentive Plan.